Bruker

According to CEO Frank Laukien mass-spectrometry sales rose in the double digits for the quarter "driven by the compelling capabilities of our high-performance products."

CEOs at four of the five leading mass spec firms saw their total compensation dip last year, according to information provided in their proxy statements, with Bill Sullivan at Agilent taking the biggest hit, a 39 percent drop from his 2007 earnings. Meanwhile, Frank Laukien at Bruker received an 80 percent upgrade in 2008.

In a competitive field where deals linking two mass-spec technologies from different vendors are unusual, the partnership could help Bio-Rad make relevant a technology that has failed to capture the interest of the research community.

While Pittcon historically has been the venue of choice for debuting new proteomics tools, major vendors this year focused on applied markets, earlier instrument launches, and the newly cash-rich NIH.

Though the firm's revenues were down year over year for the quarter, its full-year 2008 revenues increased 7 percent. Investors also sent Bruker's shares up in early trade, as the firm handily beat analysts' consensus estimate for EPS.

The Danish liquid-chromatography and bioinformatics firm plans to use the funding to help it break even and build out its sales and marketing efforts.

Pages

The New York Times Magazine writes that proteomics might be better poised than genomics to say when someone is falling ill.

Bloomberg profiles IndieBio, a startup incubator for the life sciences.

In an editorial, Nature calls for the end to the exploitation of foreign postdocs.

In Nucleic Acids Research this week: collection of epigenome-wide association study data, updated BloodSpot database, and more.